{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:16:43Z","timestamp":1789769803255,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ctrv.2026.103092","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:30:33Z","timestamp":1768609833000},"page":"103092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["De-escalation strategies for axillary management at primary surgery in early breast cancer: insights and implications for medical oncology practice"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2004-4644","authenticated-orcid":false,"given":"Irene","family":"Persano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Licata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Piras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arisa","family":"Ata-Shiroshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo Maria","family":"Naldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Bosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Notini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Chiavassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Patan\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Zanibelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Rognone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Zambelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Zucchinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Guarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Pasetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Di Micco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreste Davide","family":"Gentilini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7280-361X","authenticated-orcid":false,"given":"Giulia","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctrv.2026.103092_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103092_b0010","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ctrv.2026.103092_b0015","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1200\/JCO.2006.07.4062","article-title":"American College of Surgeons Oncology Group. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011","volume":"25","author":"Lucci","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103092_b0020","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa012782","article-title":"A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer","volume":"349","author":"Veronesi","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103092_b0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103092_b0030","unstructured":"National Comprehensive Cancer Network: Breast Cancer (version 2.2025). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"issue":"27","key":"10.1016\/j.ctrv.2026.103092_b0035","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.21.00934","article-title":"Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline","volume":"39","author":"Brackstone","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103092_b0040","doi-asserted-by":"crossref","unstructured":"Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, et al. Panelists of the St. Gallen International Breast Cancer Consensus 2025. Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer. Ann Oncol. 2025:S0923-7534(25)04718-0. doi: 10.1016\/j.annonc.2025.09.007.","DOI":"10.1016\/j.annonc.2025.09.007"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103092_b0045","first-page":"1557","article-title":"SOUND Trial Group. Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial. JAMA","volume":"9","author":"Gentilini","year":"2023","journal-title":"Oncol."},{"issue":"11","key":"10.1016\/j.ctrv.2026.103092_b0050","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMoa2412063","article-title":"Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial","volume":"392","author":"Reimer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103092_b0055","unstructured":"Schipper RJ, van Roozendaal LM, Wintraecken VM, Simons JM, Moossdorff M, Luiten EJT, et al . Omission of sentinel lymph node biopsy in clinically T1-2 node-negative breast cancer patients treated with breast-conserving therapy: results of the Dutch BOOG 2013-08 randomized controlled trial after a median follow-up of 5 years [GS2-11]. San Antonio Breast Cancer Symposium; 9-12 December 2025; San Antonio, TX."},{"issue":"10","key":"10.1016\/j.ctrv.2026.103092_b0060","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103092_b0065","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.22.01565","article-title":"Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial","volume":"41","author":"Bartels","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103092_b0070","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ejso.2016.12.011","article-title":"Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial","volume":"43","author":"S\u00e1volt","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103092_b0075","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.1245\/s10434-022-11866-w","article-title":"SINODAR-ONE Collaborative Group. Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial","volume":"29","author":"Tinterri","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"10.1016\/j.ctrv.2026.103092_b0080","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMoa2313487","article-title":"SENOMAC Trialists' Group. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases","volume":"390","author":"de Boniface","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103092_b0085","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ccell.2017.07.005","article-title":"Genomic Evolution of Breast Cancer Metastasis and Relapse","volume":"32","author":"Yates","year":"2017","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103092_b0090","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1002\/(SICI)1097-0142(19961101)78:9<1921::AID-CNCR12>3.0.CO;2-#","article-title":"Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy","volume":"78","author":"Gage","year":"1996","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103092_b0095","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.1038\/s41467-022-34581-2","article-title":"Single cell profiling of primary and paired metastatic lymph node tumors in breast cancer patients","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2026.103092_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102793","article-title":"Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome","volume":"56","author":"Venet","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ctrv.2026.103092_b0105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.breast.2022.02.013","article-title":"SENOMAC Trialists' Group. Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial","volume":"63","author":"Appelgren","year":"2022","journal-title":"Breast"},{"issue":"13","key":"10.1016\/j.ctrv.2026.103092_b0110","doi-asserted-by":"crossref","first-page":"9843","DOI":"10.1245\/s10434-025-18097-9","article-title":"Management and Outcomes in Patients with Breast Cancer with 1-of-1 and 2-of-2 Positive Sentinel Nodes","volume":"32","author":"Lyons","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103092_b0115","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41523-025-00757-4","article-title":"Predicting pathologic \u2265N2 disease in women with breast cancer","volume":"11","author":"Wanis","year":"2025","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103092_b0120","doi-asserted-by":"crossref","unstructured":"Johnston S, Martin M, O'Shaughnessy J, Hegg R, Tolaney SM, Guarneri V, et al. Overall survival with abemaciclib in early breast cancer. Ann Oncol. 2025:S0923-7534(25)04948-8. doi: 10.1016\/j.annonc.2025.10.005.","DOI":"10.1016\/j.annonc.2025.10.005"},{"issue":"14","key":"10.1016\/j.ctrv.2026.103092_b0125","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1200\/JCO-25-00099","article-title":"Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update","volume":"43","author":"Park","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103092_b0130","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S1470-2045(24)00350-4","article-title":"SENOMAC Trialists\u2019 Group. Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4\/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial","volume":"25","author":"de Boniface","year":"2024","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103092_b0135","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus Endocrine Therapy in Early Breast Cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103092_b0140","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1001\/jamaoncol.2025.3700","article-title":"Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive\/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial","volume":"11","author":"Fasching","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103092_b0145","doi-asserted-by":"crossref","unstructured":"Crown JP, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Bardia A, et al. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in HR+\/HER2\u2212 early breast cancer: NATALEE 5-year outcomes [abstract LBA14]. ESMO Congress; 17\u201321 October 2025; Berlin, Germany.","DOI":"10.1016\/j.annonc.2025.09.024"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103092_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105304","article-title":"Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+\/HER2- early breast cancer: a United States Electronic Health Records database analysis","volume":"10","author":"Tarantino","year":"2025","journal-title":"ESMO Open"},{"issue":"28","key":"10.1016\/j.ctrv.2026.103092_b0155","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1200\/JCO-25-00742","article-title":"Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive\/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay","volume":"43","author":"Bidard","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103092_b0160","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/cncr.29903","article-title":"Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status","volume":"122","author":"Shah","year":"2016","journal-title":"Cancer"},{"issue":"25","key":"10.1016\/j.ctrv.2026.103092_b0165","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for Patients withBRCA1- orBRCA2-Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103092_b0170","doi-asserted-by":"crossref","unstructured":"Garber JE, Tung NM, Domchek SM, Mayer IA, Yerushalmi R, Tolaney SM, et al. OLYMPIA \u2014 Phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1\/BRCA2 pathogenic variants and high-risk HER2-negative primary breast cancer: longer-term follow-up [Abstract GS1-09]. San Antonio Breast Cancer Symposium; 10\u201313 December 2024; San Antonio, TX.","DOI":"10.1158\/1557-3265.SABCS24-GS1-09"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103092_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.110445","article-title":"AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025","volume":"51","author":"Reimer","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103092_b0180","unstructured":"Hildebrandt G, Stachs A, Veselinovic K, Kuehn T, Heil J, Polata S et al. Insights of applied radiotherapy among patients undergoing breast-conserving surgery with or without axillary sentinel lymph node biopsy: secondary results from the INSEMA trial [GS2-03]. San Antonio Breast Cancer Symposium; 9-12 December 2025; San Antonio, TX."},{"issue":"1","key":"10.1016\/j.ctrv.2026.103092_b0185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10549-023-07227-0","article-title":"Real-world use of multigene signatures in early breast cancer: differences to clinical trials","volume":"205","author":"Licata","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"10.1016\/j.ctrv.2026.103092_b0190","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1200\/JCO.22.00069","article-title":"Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update","volume":"40","author":"Andre","year":"2022","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.ctrv.2026.103092_b0195","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","article-title":"Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer","volume":"380","author":"Sparano","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103092_b0200","doi-asserted-by":"crossref","unstructured":"Harbeck N, Gluz O, Christgen M, Untch M, Cortes J, Bianchini G, et al. Ribociclib plus endocrine therapy vs standard-of-care chemotherapy in intermediate-risk HR+\/HER2\u2212 early breast cancer: results from the neoadjuvant cohort of the phase III WSG ADAPTcycle trial [abstract 189O]. ESMO Breast Cancer; 14\u201317 May 2025; Munich, Germany.","DOI":"10.1016\/j.esmoop.2025.104743"},{"key":"10.1016\/j.ctrv.2026.103092_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115519","article-title":"[18F] FDG PET\/MRI vs sentinel node biopsy for axillary staging of early breast cancer patients. A prospective single-arm trial","volume":"224","author":"Di Micco","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103092_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103460","article-title":"Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in invasive breast cancer: A machine learning, multicenter study","volume":"69","author":"Yu","year":"2021","journal-title":"EBioMedicine"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722600006X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722600006X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:55:35Z","timestamp":1770479735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573722600006X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":42,"alternative-id":["S030573722600006X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103092","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De-escalation strategies for axillary management at primary surgery in early breast cancer: insights and implications for medical oncology practice","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103092"}}